FOR PREVIEW ONLY (Print)

David Q. Shih, MD

Assistant Director, Basic Science Research in the Inflammatory Bowel and Immunobiology Research Institute

David Q. Shih, MD

Assistant Director, Basic Science Research in the Inflammatory Bowel and Immunobiology Research Institute

  • IM/Gastroenterology

Celiac Disease

Colonoscopy

Crohn's Disease

Gastrointestinal Bleeding

Gastroscopy

Immunotherapy

Inflammatory Bowel Disease (IBD)

Ulcerative Colitis

The research focus of David Q Shih, MD, is to better understand the functional effect of genetic variants of inflammatory bowel disease (IBD) genes, autophagy, and host-microbe interaction in the immunopathophysiology of IBD through the use of molecular, cellular, genetically modified mice, and human tissue models.

View NIH Biographical Sketch as a PDF

  • Medical School: Weill Medical College of Cornell University, 2003
  • Residency: Stanford Medical Center, 2005
  • Fellowship: UCLA, 2009
  • American Gastroenterological Association, Current
  • Los Angeles Rising Star, LA Magazine/Superdoctors.com, Current
  • Pharmacy & Therapeutics Committee, Current
  • Editorial Board Member: World Journal of Gastroenterology, Current
  • MENSA International, Current
  • Reviewer: Gastroenterology, Current
  • Reviewer: The Journal of Experimental Medicine, Current

Show moreShow less

  • Barrett R, Zhang X, Koon HW, Vu M, Chang JY, Yeager N, Nguyen MA, Michelsen KS, Berel D, Pothoulakis C, Targan SR, Shih DQ. Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. Am J Pathol. 2012 Feb;180(2):636-649.
  • Koon HW, Shih DQ, Chen J, Bakirtzi K, Hing TC, Law I, Ho S, Ichikawa R, Zhao D, et al. Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology. 2011 Nov;141(5):1852-1863.
  • Vora P, Shih DQ, McGovern DP, Targan SR. Current concepts on the immunopathogenesis of inflammatory bowel disease. Front Biosci (Elite Ed). 2012 Jan 1;4:1451-1477.
  • Amin J, Huang B, Yoon J, Shih DQ. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis. 2015 Feb;21(2):445-452.
  • Shih DQ, Zheng L, Zhang X, Zhang H, Kanazawa Y, Ichikawa R, Wallace KL, Chen J, Pothoulakis C, et al. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol. 2014 Nov;7(6):1492-1503.
  • Sidhu-Varma M, Shih DQ, Targan SR. Differential levels of Tl1a affect the expansion and function of regulatory T cells in modulating murine colitis. Inflamm Bowel Dis. 2016 Mar;22(3):548-559.

Show moreShow less

English

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.

Send Email to David Q. Shih, MD